Skin cancer is the most commonly occurring cancer in the United States. After the age of 65, 50%of the population will develop skin cancer with the majority diagnosed with Basal Cell Carcinoma (BCC). BCC occurs typically on the face, head or neck and is a highly disfiguring disease. Current therapies involve invasive surgical procedures that are time-consuming, associated with patient recovery/morbidity and are expensive. PatchIT
is novel, single use, topical drug delivery patch that, like a 'Band-Aid', is applied to the affected skin of those diagnosed with skin cancer. It is based on a proprietary Micro-Needle Array drug delivery platform that uniquely delivers a potent generic chemotherapeutic agent and modifier to kill existing skin cancer and induce a memory immune response to prevent cancer re-occurrence. This project has confirmed high physician and patient acceptance from initial customer feedback and has already received immense interest from investors at all showcased platforms.